Prelude Therapeutics (NASDAQ: PRLD) cures Nasdaq bid-price deficiency

Rhea-AI Filing Summary

Prelude Therapeutics has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq notified the company on September 18, 2025 that its common stock once again meets the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2).

This resolves the earlier deficiency notice received in March 2025 and closes the matter, removing the immediate risk of non-compliance with Nasdaq’s continued listing standards for the company’s common stock.

Insights

Equity listing and market-structure analyst

Prelude resolves prior Nasdaq bid-price deficiency and removes near-term delisting risk.

Prelude Therapeutics previously received a Nasdaq notice on March 27, 2025 for failing to meet the $1.00 minimum bid price requirement for its common stock. Such notices can ultimately lead to delisting if not cured within the allotted compliance period.

On September 18, 2025, Nasdaq confirmed the company has regained compliance with Listing Rule 5550(a)(2) and that the matter is closed. This means the stock has traded at or above the required minimum long enough for Nasdaq to restore full compliance status.

While this event does not change the company’s underlying business, it removes a structural overhang related to listing status. Future company filings will indicate if any new listing compliance issues arise or if Nasdaq standards change in a way that affects the common stock.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/19/2025 - 07:41 AM Learn about SEC filing dates

FAQ

What did Prelude Therapeutics (PRLD) announce in this 8-K filing?

Prelude Therapeutics announced it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq informed the company on September 18, 2025 that its common stock now meets Listing Rule 5550(a)(2), and the prior deficiency matter has been formally closed.

Why was Prelude Therapeutics (PRLD) previously out of compliance with Nasdaq rules?

Prelude Therapeutics was previously out of compliance because its common stock failed to meet Nasdaq’s $1.00 per share minimum bid price requirement. Nasdaq notified the company of this deficiency in a letter dated March 27, 2025, referencing Listing Rule 5550(a)(2).

When did Prelude Therapeutics (PRLD) regain compliance with Nasdaq’s minimum bid price?

Prelude Therapeutics regained compliance on September 18, 2025, when Nasdaq sent a confirmation letter. That letter stated the company again meets the minimum bid price requirement and that the previous deficiency matter related to Listing Rule 5550(a)(2) is now closed.

What Nasdaq rule is relevant to Prelude Therapeutics’ (PRLD) compliance update?

The relevant rule is Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price requirement at $1.00 per share. Prelude Therapeutics’ 8-K states that Nasdaq has determined the company now satisfies this standard for continued listing of its common stock.

Does the 8-K indicate any continued listing risk for Prelude Therapeutics (PRLD)?

The 8-K states that Nasdaq has notified Prelude Therapeutics the minimum bid price matter is closed. This indicates the specific prior deficiency has been resolved. The filing does not mention any ongoing Nasdaq compliance issues related to the company’s common stock.

0001678660false00016786602025-09-182025-09-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

Prelude Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39527				81-1384762
(State or other jurisdiction of incorporation or organization)		(Commission File Number)				(I.R.S. Employer Identification No.)
175 Innovation Boulevard Wilmington, Delaware				19805
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (302) 467-1280

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		PRLD		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

As previously disclosed on March 28, 2025, Prelude Therapeutics Incorporated (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 27, 2025, notifying the Company that it was not in compliance with the Nasdaq Minimum Bid Price Requirement because its common stock, par value $0.0001 per share (the "Common Stock") had failed to meet the $1.00 per share Minimum Bid Price Requirement.

On September 18, 2025, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and that the matter is now closed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRELUDE THERAPEUTICS INCORPORATED
Date: September 19, 2025	By:	/s/ Bryant Lim
		Bryant Lim
		Chief Financial Officer